JP2003528084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003528084A5 JP2003528084A5 JP2001568907A JP2001568907A JP2003528084A5 JP 2003528084 A5 JP2003528084 A5 JP 2003528084A5 JP 2001568907 A JP2001568907 A JP 2001568907A JP 2001568907 A JP2001568907 A JP 2001568907A JP 2003528084 A5 JP2003528084 A5 JP 2003528084A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- disease
- optionally substituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 description 24
- -1 hydroxy, methoxy Chemical group 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 1
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 description 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 0 C*N1OC1=N Chemical compound C*N1OC1=N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 208000001969 capillary hemangioma Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Description
【特許請求の範囲】
【請求項1】 以下の式を有する化合物、またはその互変異性体あるいはそれらの薬学的に受容可能な塩であって:
【化1】
ここで、Q1およびQ2の各々は、5〜6員の芳香族炭素環式もしくはヘテロ環式環系、または8〜10員の二環式環系から独立して選択され、該二環式環系は、芳香族炭素環式環、芳香族へテロ環式環または芳香族炭素環式環および芳香族へテロ環式環の組み合わせを含み;
ここで、Q1を形成する環は、1〜4の置換基によって任意に置換され、該置換基の各々は、J;ハロ;NR’2、OR’、CO2R’もしくはCONR’2によって任意に置換されるC1〜C4アルキル;A、T−C(O)R’、OPO3H2、NR’2、NR’2、OR’、CO2R’もしくはCONR’2によって任意に置換されるO−(C1〜C4)−アルキル;NR’2;OCF3;CF3;NO2;CO2R’;CONR’;SR’;S(O2)N(R’)2;SCF3;CN;N(R’)C(O)R4;N(R’)C(O)OR4;N(R’)C(O)C(O)R4;N(R’)S(O2)R4;N(R’)R4;N(R4)2;OR4;OC(O)R4;OP(O)3H2;またはN=C−N(R’)2から独立して選択され;ここで、
Q2を形成する環は、Jによって置換され、そして、ハロ、C1〜C4直鎖アルキルもしくは分枝アルキル、ヒドロキシ、メトキシ、トリフルオロメチル、トリフルオロメトキシ、シアノ、またはアミノによって任意に置換され;
Jは、A、−T−C(O)R’または−OPO3H2から選択される1〜3の置換基によって置換されるC1〜C4直鎖アルキル誘導体または分枝アルキル誘導体であって;
Aは、以下の群より選択され:
【化2】
Tは、OまたはNHのいずれかであり;
Gは、NH2またはOHのいずれかであり;
Zは、CHまたはNのいずれかであり;
R’は、水素、(C1〜C3)−アルキル、(C2〜C3)−アルケニルまたは(C2〜C3)−アルキニル、フェニルまたはハロ、メトキシ、シアノ、ニトロ、アミノ、ヒドロキシ、メチルもしくはエチルから独立して選択される1〜3個の置換基によって置換されるフェニル、あるいはハロ、メトキシ、シアノ、ニトロ、アミノ、ヒドロキシ、メチルもしくはエチルから独立して選択される1〜3個の置換基によって任意に置換される5〜6員のヘテロ環式環系から選択され;
R3は、5〜6員の芳香族炭素環式またはへテロ環式環系から選択され;
R4は、N(R’)2、OR’、CO2R’、CON(R’)2もしくはSO2N(R2)2によって任意に置換される(C1〜C4)−アルキル;(C1〜C4)分枝または直鎖アルキル基、N(R’)2、OR’、CO2R’、CON(R’)2もしくはSO2N(R2)2によって任意に置換される5〜6員の炭素環式またはへテロ環式環系;あるいは(C1〜C4)分枝または直鎖アルキル基、N(R’)2、OR’、CO2R’、CON(R’)2もしくはSO2N(R2)2によって任意に置換される5〜6員の炭素環式またはへテロ環式環系によって任意に置換される(C1〜C4)−アルキルであって;
R2は、水素、(C1〜C3)−アルキル、または(C1〜C3)−アルケニルから選択され;各々が−N(R’)2、−OR’、SR’、−C(O)−N(R’)2、−S(O2)−N(R’)2、−C(O)−OR’もしくはR3によって任意に置換され;そして
Wは、H;N(R2)SO2−N(R2)2;N(R2)SO2−N(R2)(R3);N(R2)C(O)−OR2;N(R2)C(O)−N(R2)2;N(R2)C(O)−N(R2)(R3);N(R2)C(O)−R2;N(R2)2;C(O)−R2;CH(OH)−R2;C(O)−N(R2)2;C(O)−OR2;あるいはA、T−(CO)R’、N(R’)2、OR’、CO2R’、CON(R’)2、R3もしくはSO2N(R2)2によって任意に置換される(C1〜C4)直鎖または分枝アルキル;あるいはN(R’)2、OR’、CO2R’、CON(R’)2もしくはSO2N(R2)2によって任意に置換される5〜6員の炭素環式またはへテロ環式環系から選択される、
化合物。
【請求項2】 請求項1に記載の化合物であって、ここで、Q1は、クロロ、フルオロ、ブロモ、−CH3、−OCH3、−OH、−CF3、−OCF3、−O(CH2)2CH3、NH2、3,4−メチレンジオキシ、−N(CH3)2、−NH−S(O)2−フェニル、−NH−C(O)O−CH2−4−ピリジン、−NH−C(O)CH2−モルフォリン、−NH−C(O)CH2−N(CH3)2、−NH−C(O)CH2−ピペラジン、−NH−C(O)CH2−ピロリジン、−NH−C(O)C(O)−モルフォリン、−NH−C(O)C(O)−ピペラジン、−NH−C(O)C(O)−ピロリジン、−O−C(O)CH2−N(CH3)2または−O−(CH2)2−N(CH3)2から独立して選択される1〜3個の置換基を含むフェニルあるいはピリジルから選択され、そしてここで、該置換基の少なくとも1つがオルト位にある、化合物。
【請求項3】 Q1が、少なくとも2つの置換基を含み、該置換基の両方がオルト位にある、請求項2に記載の化合物。
【請求項4】 請求項2に記載の化合物であって、ここで、Q1は、以下:
【化3】
から選択される、化合物。
【請求項5】 請求項4に記載の化合物であって、ここで、Q1は、2−フルオロ−6−トリフルオロメチルフェニル;2,6−ジフルオロフェニル;2,6−ジクロロフェニル;2−クロロ−4−ヒドロキシフェニル;2−クロロ−4−アミノフェニル;2,6−ジクロロ−4−アミノフェニル;2,6−ジクロロ−3−アミノフェニル;2,6−ジメチル−4−ヒドロキシフェニル;2−メトキシ−3,5−ジクロロ−4−ピリジル;2−クロロ−4,5−メチレンジオキシフェニルまたは2−クロロ−4−(N−2−モルフォリノ−アセトアミド)フェニルから選択される、化合物。
【請求項6】 請求項1に記載の化合物であって、ここで、Q2は、フェニルまたはピリジルから選択され、該フェニルまたは該ピリジルは、置換基Jおよび0〜3個の他の置換基を含み、ここで、該他の置換基の各々は、クロロ、フルオロ、ブロモ、メチル、エチル、イソプロピル、−OCH3、−OH、−NH2、−CF3、−OCF3、−SCH3、−OCH3、−C(O)OH、−C(O)OCH3、−CH2NH2、−N(CH3)2、−CH2−ピロリジンおよび−CH2OHから独立して選択される、化合物。
【請求項7】 前記化合物が、化合物15
【化4】
である、請求項1に記載の化合物。
【請求項8】 前記化合物が、化合物16
【化5】
である、請求項1に記載の化合物。
【請求項9】 請求項1に記載の化合物であって、該化合物が、以下:
【化6】
である、化合物。
【請求項10】 請求項1に記載の化合物であって、該化合物が、以下:
【化7】
である、化合物。
【請求項11】 請求項1に記載の化合物および薬学的に受容可能なキャリアを含む、組成物。
【請求項12】 患者における炎症性疾患、自己免疫性疾患、破壊性骨障害、増殖性障害、感染性疾患、神経変性疾患、アレルギー、発作の再灌流/虚血、心臓発作、脈管形成障害、器官低酸素症、血管過形成、心臓肥大、トロンビン誘導血小板凝集またはプロスタグランジンエンドペルオキシダーゼシンターゼ−2関連状態を処置または予防するための組成物であって、該組成物が、p38を阻害するのに有効である、組成物。
【請求項13】 前記組成物が、急性膵炎、慢性膵炎、喘息、アレルギー、または成人性呼吸窮迫症候群から選択される炎症性疾患を処置または予防するために使用される、請求項12に記載の組成物。
【請求項14】 前記組成物が、糸球体腎炎、慢性関節リウマチ、全身性エリテマトーデス、強皮症、慢性甲状腺炎、グレーヴス病、自己免疫性胃炎、糖尿病、自己免疫性溶血性貧血、自己免疫性好中球減少症、血小板減少症、アトピー性皮膚炎、慢性活性肝炎、重症筋無力症、多発性硬化症、炎症性腸疾患、潰瘍性大腸炎、クローン病、乾癬、または対宿主性移植片病から選択される自己免疫性疾患を処置または予防するために使用される、請求項12に記載の組成物。
【請求項15】 前記組成物が、変形性関節症、骨粗鬆症または多発性骨髄腫関連骨障害から選択される破壊性骨障害を処置または予防するために使用される、請求項12に記載の組成物。
【請求項16】 前記組成物が、急性骨髄性白血病、慢性骨髄性白血病、転移性黒色腫、カポージ肉腫、または多発性骨髄腫から選択される増殖性疾患を処置または予防するために使用される、請求項12に記載の組成物。
【請求項17】 前記組成物が、敗血症、敗血性ショック、または細菌性赤痢から選択される感染性疾患を処置または予防するために使用される、請求項12に記載の組成物。
【請求項18】 前記組成物が、急性肝炎感染、HIV感染またはCMV網膜炎から選択されるウイルス性疾患を処置または予防するために使用される、請求項12に記載の組成物。
【請求項19】 前記組成物が、アルツハイマー病、パーキンソン病、大脳虚血から選択される神経変性疾患または外傷性損傷により引き起こされる神経変性疾患を処置または予防するために使用される、請求項12に記載の組成物。
【請求項20】 前記組成物が、発作の虚血/再灌流または心筋虚血、腎性虚血、心臓発作、器官低酸素症またはトロンビン誘導血小板凝集を処置または予防するために使用される、請求項12に記載の組成物。
【請求項21】 前記組成物が、浮腫、発熱、無痛覚症または疼痛から選択されるプロスタグランジンエンドペルオキシドシンターゼ−2と関連した状態を処置または予防するために使用される、請求項12に記載の組成物。
【請求項22】 前記疼痛が、神経筋痛、頭痛、癌痛、歯痛または関節炎痛から選択される、請求項21に記載の組成物。
【請求項23】 前記組成物が、固形腫瘍、眼性新生血管形成、または乳児血管腫から選択される脈管形成障害を処置または予防するために使用される、請求項12に記載の組成物。
[Claims]
1. A compound having the formula: or a tautomer or pharmaceutically acceptable salt thereof,
Embedded image
Wherein each of Q 1 and Q 2 is independently selected from a 5- to 6-membered aromatic carbocyclic or heterocyclic ring system, or an 8- to 10-membered bicyclic ring system; The formula ring system comprises an aromatic carbocyclic ring, an aromatic heterocyclic ring or a combination of an aromatic carbocyclic ring and an aromatic heterocyclic ring;
Here, the ring forming Q 1 is optionally substituted with 1 to 4 substituents, each of which is substituted by J; halo; NR ′ 2 , OR ′, CO 2 R ′ or CONR ′ 2 C 1 -C 4 alkyl optionally substituted; a, T-C (O ) R ', OPO 3 H 2, NR' 2, NR '2, oR', CO 2 R ' or CONR' arbitrarily by 2 Substituted O- (C 1 -C 4 ) -alkyl; NR ′ 2 ; OCF 3 ; CF 3 ; NO 2 ; CO 2 R ′; CONR ′; SR ′; S (O 2 ) N (R ′) 2 N (R ′) C (O) R 4 ; N (R ′) C (O) OR 4 ; N (R ′) C (O) C (O) R 4 ; N (R ′); SCF 3 ; CN; ) S (O 2) R 4 ; N (R ') R 4; N (R 4) 2; oR 4; OC (O) R 4; OP (O) 3 H 2; or N = C-N (R ') 2 or Independently selected; wherein
Ring to form a Q 2 are substituted by J, and, substituted halo, C 1 -C 4 linear alkyl or branched alkyl, hydroxy, methoxy, trifluoromethyl, trifluoromethoxy, optionally cyano or by an amino, Done;
J is a in A, -T-C (O) R ' or C 1 -C 4 straight chain alkyl derivatives or branched alkyl derivative substituted by 1 to 3 substituents selected from -OPO 3 H 2 hand;
A is selected from the following groups:
Embedded image
T is either O or NH;
G is either NH 2 or OH;
Z is either CH or N;
R ′ is hydrogen, (C 1 -C 3 ) -alkyl, (C 2 -C 3 ) -alkenyl or (C 2 -C 3 ) -alkynyl, phenyl or halo, methoxy, cyano, nitro, amino, hydroxy, Phenyl substituted by 1 to 3 substituents independently selected from methyl or ethyl, or 1 to 3 independently selected from halo, methoxy, cyano, nitro, amino, hydroxy, methyl or ethyl Selected from a 5-6 membered heterocyclic ring system optionally substituted by a substituent of
R 3 is selected from a 5-6 membered aromatic carbocyclic or heterocyclic ring system;
R 4 is (C 1 -C 4 ) -alkyl optionally substituted by N (R ′) 2 , OR ′, CO 2 R ′, CON (R ′) 2 or SO 2 N (R 2 ) 2 ; (C 1 -C 4 ) branched or linear alkyl group, optionally substituted by N (R ′) 2 , OR ′, CO 2 R ′, CON (R ′) 2 or SO 2 N (R 2 ) 2 that 5-6 carbocyclic or heterocyclic ring system of members; or (C 1 ~C 4) branched or straight chain alkyl groups, N (R ') 2, oR', CO 2 R ', CON ( R ′) with (C 1 -C 4 ) -alkyl optionally substituted by a 5-6 membered carbocyclic or heterocyclic ring system optionally substituted by 2 or SO 2 N (R 2 ) 2 There;
R 2 is hydrogen, (C 1 ~C 3) - alkyl, or (C 1 ~C 3) - is selected from alkenyl; each -N (R ') 2, -OR ', SR ', - C ( O) -N (R ') 2 , -S (O 2) -N (R' being optionally substituted by) 2, -C (O) -OR ' , or R 3; and W is, H; N (R 2) SO 2 -N (R 2 ) 2; N (R 2) SO 2 -N (R 2) (R 3); N (R 2) C (O) -OR 2; N (R 2) C ( O) -N (R 2) 2 ; N (R 2) C (O) -N (R 2) (R 3); N (R 2) C (O) -R 2; N (R 2) 2; C (O) -R 2; CH (OH) -R 2; C (O) -N (R 2) 2; C (O) -OR 2; or A, T- (CO) R ' , N (R ') 2, OR', CO 2 R ', CON (R') 2, R 3 if It is optionally substituted by SO 2 N (R 2) 2 (C 1 ~C 4) straight or branched alkyl; or N (R ') 2, OR ', CO 2 R ', CON (R') Selected from 5 or 6 membered carbocyclic or heterocyclic ring systems optionally substituted by 2 or SO 2 N (R 2 ) 2 ;
Compound.
2. The compound according to claim 1, wherein Q 1 is chloro, fluoro, bromo, —CH 3 , —OCH 3 , —OH, —CF 3 , —OCF 3 , —O (CH 2) 2 CH 3, NH 2, 3,4- methylenedioxy, -N (CH 3) 2, -NH-S (O) 2 - phenyl, -NH-C (O) O -CH 2 - 4-pyridine, -NH-C (O) CH 2 - morpholine, -NH-C (O) CH 2 -N (CH 3) 2, -NH-C (O) CH 2 - piperazine, -NH-C (O) CH 2 - pyrrolidine, -NH-C (O) C (O) - morpholine, -NH-C (O) C (O) - piperazine, -NH-C (O) C (O) - pyrrolidine , -O-C (O) CH 2 -N (CH 3) 2 or -O- (CH 2) 2 -N ( CH 3) 2 Is selected from phenyl or pyridyl containing 1 to 3 substituents stand to be selected, and wherein, in at least one ortho position of the substituent, compound.
3. The compound of claim 2, wherein Q 1 contains at least two substituents, both of which are in the ortho position.
4. The compound of claim 2, wherein Q 1 is:
Embedded image
A compound selected from:
5. The compound according to claim 4, wherein Q 1 is 2-fluoro-6-trifluoromethylphenyl; 2,6-difluorophenyl; 2,6-dichlorophenyl; 2-chloro 2-hydroxy-4-aminophenyl; 2,6-dichloro-4-aminophenyl; 2,6-dichloro-3-aminophenyl; 2,6-dimethyl-4-hydroxyphenyl; 2- Methoxy-3,5-dichloro-4-pyridyl; a compound selected from 2-chloro-4,5-methylenedioxyphenyl or 2-chloro-4- (N-2-morpholino-acetamido) phenyl.
6. The compound according to claim 1, wherein Q 2 is selected from phenyl or pyridyl, said phenyl or pyridyl being substituted J and 0 to 3 other substituents. include, where each of the other substituents are chloro, fluoro, bromo, methyl, ethyl, isopropyl, -OCH 3, -OH, -NH 2 , -CF 3, -OCF 3, -SCH 3, -OCH 3, -C (O) OH , -C (O) OCH 3, -CH 2 NH 2, -N (CH 3) 2, -CH 2 - are independently selected from pyrrolidine and -CH 2 OH ,Compound.
7. The compound according to claim 7, wherein the compound is Compound 15.
Embedded image
The compound of claim 1, wherein
8. The compound according to claim 8, wherein the compound is
Embedded image
The compound of claim 1, wherein
9. The compound according to claim 1, wherein the compound is:
Embedded image
A compound.
10. The compound according to claim 1, wherein the compound is:
Embedded image
A compound.
11. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
12. An inflammatory disease, autoimmune disease, destructive bone disorder, proliferative disorder, infectious disease, neurodegenerative disease, allergy, stroke reperfusion / ischemia, heart attack, angiogenesis disorder in a patient. A composition for treating or preventing organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin-induced platelet aggregation or prostaglandin endoperoxidase synthase-2-related condition, wherein the composition inhibits p38 effective der to Ru, composition.
13. The method of claim 12, wherein the composition is used to treat or prevent an inflammatory disease selected from acute pancreatitis, chronic pancreatitis, asthma, allergy, or adult respiratory distress syndrome. Composition .
14. The composition according to claim 1, wherein said composition is glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmunity. Neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, or graft versus host 13. The composition according to claim 12, which is used for treating or preventing an autoimmune disease selected from diseases.
15. The composition of claim 12, wherein the composition is used to treat or prevent a destructive bone disorder selected from osteoarthritis, osteoporosis or multiple myeloma-related bone disorder. Thing .
16. The composition is used to treat or prevent a proliferative disease selected from acute myeloid leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, or multiple myeloma. A composition according to claim 12.
17. The composition, sepsis, are used to septic shock treatment or prevention or infectious disease selected from shigellosis, The composition of claim 12.
18. The composition is, acute hepatitis infection, it is used to treat or prevent viral disease selected from HIV infection or CMV retinitis, composition according to claim 12.
19. The composition of claim 12, wherein the composition is used to treat or prevent a neurodegenerative disease selected from Alzheimer's disease, Parkinson's disease, cerebral ischemia or a neurodegenerative disease caused by traumatic injury. A composition according to claim 1 .
20. The composition is used to treat or prevent stroke ischemia / reperfusion or myocardial ischemia, renal ischemia, heart attack, organ hypoxia or thrombin-induced platelet aggregation. The composition according to claim 12.
21. The composition of claim 12, wherein the composition is used to treat or prevent a condition associated with prostaglandin endoperoxide synthase-2 selected from edema, fever, analgesia or pain. A composition as described.
22. The composition according to claim 21, wherein said pain is selected from neuromuscular pain, headache, cancer pain, toothache or arthritis pain.
23. The composition according to claim 12, wherein the composition is used to treat or prevent an angiogenic disorder selected from solid tumors, ocular neovascularization, or infantile hemangiomas . .
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19135800P | 2000-03-22 | 2000-03-22 | |
US60/191,358 | 2000-03-22 | ||
PCT/US2001/009256 WO2001070695A1 (en) | 2000-03-22 | 2001-03-22 | Pyridine derivatives as inhibitors of p38 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2003528084A JP2003528084A (en) | 2003-09-24 |
JP2003528084A5 true JP2003528084A5 (en) | 2008-05-08 |
Family
ID=22705152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001568907A Withdrawn JP2003528084A (en) | 2000-03-22 | 2001-03-22 | inhibitors of p38 |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP2003528084A (en) |
AU (1) | AU2001247700A1 (en) |
CA (1) | CA2403828A1 (en) |
MX (1) | MXPA02009319A (en) |
TW (1) | TWI282334B (en) |
WO (1) | WO2001070695A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001283237B2 (en) | 2000-08-11 | 2007-09-20 | Vertex Pharmaceuticals Incorporated | Pyridine derivatives as inhibitors of p38 |
GB0124933D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
MXPA04007838A (en) | 2002-02-12 | 2004-10-15 | Smithkline Beecham Corp | Nicotinamide derivates useful as p38 inhibitors. |
GB0308201D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308186D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
GB0908317D0 (en) * | 2009-05-14 | 2009-06-24 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6147080A (en) * | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US5945418A (en) * | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
WO1998052941A1 (en) * | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
ES2155817T3 (en) * | 1997-12-22 | 2007-06-16 | Bayer Pharmaceuticals Corp. | INHIBITION OF THE ACTIVITY OF QUINASA P38 USING HETEROCICLIC UREAS REPLACED WITH ARILO AND HETEROARILO. |
MY132496A (en) * | 1998-05-11 | 2007-10-31 | Vertex Pharma | Inhibitors of p38 |
-
2001
- 2001-03-22 MX MXPA02009319A patent/MXPA02009319A/en not_active Application Discontinuation
- 2001-03-22 AU AU2001247700A patent/AU2001247700A1/en not_active Abandoned
- 2001-03-22 CA CA002403828A patent/CA2403828A1/en not_active Abandoned
- 2001-03-22 JP JP2001568907A patent/JP2003528084A/en not_active Withdrawn
- 2001-03-22 TW TWNOVELCOMA patent/TWI282334B/en not_active IP Right Cessation
- 2001-03-22 WO PCT/US2001/009256 patent/WO2001070695A1/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002526482A5 (en) | ||
JP2002517486A5 (en) | ||
JP2002514625A5 (en) | ||
JP2002526501A5 (en) | ||
CA2331460A1 (en) | Heterocyclic inhibitors of p38 | |
CA2496676A1 (en) | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands | |
RU2344123C2 (en) | 3,4-disubstituted cyclobutene-1,2-diones as ligands of cxc-chemokine receptor | |
ES2202658T3 (en) | REPLACED HETEROCICLES CONTAINING NITROGEN AS INHIBITORS OF PROTEIN-KINASE P38. | |
RU2495044C2 (en) | Protein tyrosine kinase activity inhibitors | |
JP2018507238A5 (en) | ||
RU2012105914A (en) | EFFECTIVE LOW-MOLECULAR AUTOPHAGIA INHIBITORS AND METHOD OF APPLICATION | |
JP2003531103A5 (en) | ||
HRP20120900T1 (en) | 5-membered heterocycle-based p-38 kinase inhibitors | |
JP2003528084A5 (en) | ||
JP2006512339A5 (en) | ||
JP2018536648A5 (en) | ||
JP2013056886A5 (en) | ||
JP2010536887A5 (en) | ||
JP2005505618A5 (en) | ||
WO2003080580A3 (en) | Quinoline derivatives and their use as 5-ht6 ligands | |
JP2003519130A5 (en) | ||
CA2491895A1 (en) | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases | |
JP2007523177A5 (en) | ||
JP2018509438A5 (en) | ||
AU2001283237B2 (en) | Pyridine derivatives as inhibitors of p38 |